Advertisement
UK markets closed

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • CRUDE OIL

    82.87
    -0.49 (-0.59%)
     

  • GOLD FUTURES

    2,333.80
    -8.30 (-0.35%)
     

  • DOW

    38,427.39
    -76.30 (-0.20%)
     

  • Bitcoin GBP

    51,433.38
    -2,110.78 (-3.94%)
     

  • CMC Crypto 200

    1,385.08
    -39.02 (-2.74%)
     

  • NASDAQ Composite

    15,681.03
    -15.61 (-0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD

Zacks Equity Research

Global Blood Therapeutics, Inc. GBT announced that the FDA has approved its lead product candidate Oxbryta (voxelotor) as an oral, once-daily treatment for sickle cell disease (SCD) in patients aged 12 years and above. The approval comes almost three months ahead of the scheduled action date of Feb 26, 2020.

SCD is a chronic, inherited blood disorder that affects hemoglobin levels.

Following this nod, Oxbryta became the first approved therapy that directly inhibits sickle hemoglobin polymerization, a major cause for SCD.

Shares of Global Blood have surged 53.4% so far this year compared with the industry’s rise of 4.6%.



Meanwhile, the company is on track to initiate a post-approval confirmatory study (HOPE-KIDS 2) by this year-end on Oxbryta using transcranial doppler (TCD) flow velocity to show a reduction in stroke risk among children aged from two to 15 years.

ADVERTISEMENT

Importantly, treatment options are limited for SCD. However, Global Blood is likely to face stiff competition as many companies are developing therapies to treat the disease.

In November 2019, the FDA approved Novartis’ NVS Adakveo (crizanlizumab) to lower the frequency of vaso-occlusive crises (VOCs) or pain crises in patients with SCD, aged 16 years or above. The nod came approximately two months ahead of the FDA’s priority-review action date.

bluebird bio BLUE is also developing a LentiGlobin for the treatment of VOC in patients with SCD.

Zacks Rank & Key Pick

Global Blood currently has a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Anika Therapeutics Inc. ANIK, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Anika’s earnings estimates have been revised 16% upward for 2019 and 17.4% for 2020 over the past 60 days. The stock has rallied 71.4% so far this year.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Novartis AG (NVS) : Free Stock Analysis Report
 
bluebird bio, Inc. (BLUE) : Free Stock Analysis Report
 
Global Blood Therapeutics, Inc. (GBT) : Free Stock Analysis Report
 
Anika Therapeutics Inc. (ANIK) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research